Genomic Testing for Breast Cancer
(FLEX Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores new ways to understand breast cancer by examining the genes involved in the disease. It uses tests called MammaPrint and BluePrint to analyze the full set of genes in patients with stage I to III breast cancer. The goal is to identify patterns that could help doctors select better treatments for patients in the future. It suits individuals with a new primary breast tumor who have already undergone these specific gene tests. As an unphased study, this trial offers participants a unique opportunity to contribute to groundbreaking research that could shape future breast cancer treatments.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that MammaPrint and BluePrint testing is safe for breast cancer patients?
Research has shown that MammaPrint and BluePrint tests are generally safe for patients. These tests analyze genes to assess the risk of breast cancer recurrence. They are not treatments and do not involve medication, so they lack the side effects associated with drugs. Instead, they use a sample from a breast tumor to gather information.
Patients have found these tests easy to handle because they are non-invasive, meaning they do not enter the body or cause harm. No reports of negative effects from the testing process itself exist. Therefore, participants in studies using these tests can feel confident about their safety.12345Why are researchers excited about this trial?
Researchers are excited about using MammaPrint and BluePrint testing because these approaches offer a personalized look at breast cancer. Unlike traditional treatments that often rely on a one-size-fits-all method, these tests analyze the activity of specific genes in cancer cells, providing a detailed genetic profile. This genetic insight helps doctors tailor treatment plans more precisely, potentially improving outcomes and avoiding unnecessary treatments. By using a full-genome data chip, these tests give a comprehensive view of the tumor's characteristics, helping to guide more informed decisions about therapy.
What evidence suggests that MammaPrint and BluePrint testing could be effective for breast cancer?
Research has shown that the MammaPrint and BluePrint tests aid in treating breast cancer. In this trial, all participants will undergo both MammaPrint and BluePrint testing using the full-genome testing data chip. MammaPrint examines 70 genes to assess whether early-stage breast cancer patients are at low or high risk of recurrence. This information assists doctors in deciding if chemotherapy is necessary. Studies indicate that patients identified as high risk by MammaPrint often opt for chemotherapy, with 91% remaining cancer-free after five years. Additionally, MammaPrint can identify patients who appear high risk based on clinical factors but are low risk genetically, allowing them to potentially avoid chemotherapy and still achieve favorable outcomes. When combined with MammaPrint, BluePrint offers further insights into the tumor, aiding in the creation of personalized treatment plans.36789
Who Is on the Research Team?
Joyce O'Shaughnessy, MD
Principal Investigator
Texas Oncology - Baylor Charles A. Sammons Center
William Audeh, MD
Principal Investigator
Agendia, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
MammaPrint and BluePrint Testing
All patients receive MammaPrint and BluePrint testing using the full-genome testing data chip
Treatment
Treatment is at the discretion of the physician adhering to NCCN approved regimens
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BluePrint
- Full-Genome Testing
- MammaPrint
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
All patients will receive MammaPrint and BluePrint testing using the full-genome testing data chip. Treatment will be at the discretion of the physician while adhering to NCCN guidelines.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Agendia
Lead Sponsor
Citations
Agendia to Reveal Novel Breast Cancer Outcome Data ...
– The data reveal that patients aged ≥70 with MammaPrint High Risk tumors were less likely to receive chemotherapy. However, older women with ...
MammaPrint and BluePrint comprehensively capture the ...
MammaPrint® (MP) is a 70‐gene signature that stratifies early‐stage breast cancer patients into low‐ and high risk of distant relapse.
Association of MammaPrint index and 3-year outcome ...
Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without ...
4.
agendia.com
agendia.com/study-shows-half-of-early-stage-breast-cancer-patients-may-safely-avoid-chemotherapy/Study Shows Half of Early-Stage Breast Cancer Patients ...
Of the 208 patients who were determined to be 'high risk,” 81 percent chose chemotherapy and 91% were disease-free after five years. “MammaPrint ...
early breast cancer: FLEX Registry real-world data | JNCI ...
MINDACT has proven that MammaPrint can identify clinically high risk, genomically low risk patients who have excellent outcomes without chemotherapy, but it was ...
MammaPrint, BluePrint, and Full-genome Data Linked with ...
The FLEX Study (NCT03053193) is aggregating a large, real-world dataset, linking comprehensive clinical and full genome expression data with a ...
MammaPrint Breast Cancer Testing & Recurrence Risk
MammaPrint genomic test analyzes the 70 most important genes and provides clear answers for risk of breast cancer recurrence.
MammaPrint, BluePrint, and Full-Genome Data Linked With ...
The participant's full genome data will be used for research purposes only. MammaPrint is used to determine the patient's risk for distant metastasis (spreading ...
MammaPrint, BluePrint, and Full-genome Data Linked With ...
Tests the safety of a drug in healthy volunteers or subjects with indications. The aim is to find the best dose of a new drug with the fewest side effects ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.